⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19057043 | 0.77 | — | — | |
| SCHEMBL17130110 | 0.76 | — | — | |
| SCHEMBL11760975 | 0.76 | — | — | |
| SCHEMBL3715692 | 0.76 | — | — | |
| SCHEMBL10619642 | 0.75 | — | — | |
| SCHEMBL15332975 | 0.73 | — | — | |
| SCHEMBL17398528 | 0.72 | KDM4E (0.31) | — | |
| SCHEMBL17398708 | 0.72 | — | — | |
| SCHEMBL31239592 | 0.72 | POLB (0.33) | — | |
| SCHEMBL6871429 | 0.70 | NOS1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250158123-A1 | NONAQUEOUS ELECTROLYTE FOR NONAQUEOUS-ELECTROLYTE CELL, AND NONAQUEOUS-ELECTROLYTE CELL | PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) | 2025-05-15 | — | — | US | claimed |
| EP-4475256-A1 | NONAQUEOUS ELECTROLYTE FOR NONAQUEOUS-ELECTROLYTE CELL, AND NONAQUEOUS-ELECTROLYTE CELL | Panasonic Intellectual Property Management Co., Ltd. (JP) | 2024-12-11 | — | — | EP | claimed |
| CN-118591919-A | Nonaqueous electrolyte for nonaqueous electrolyte battery and nonaqueous electrolyte battery | 松下知识产权经营株式会社 | 2024-09-03 | — | — | CN | claimed |
| WO-2023145896-A1 | NONAQUEOUS ELECTROLYTE FOR NONAQUEOUS-ELECTROLYTE CELL, AND NONAQUEOUS-ELECTROLYTE CELL | パナソニックＩＰマネジメント株式会社 | 2023-08-03 | — | — | WO | claimed |
| CN-105461738-A | Rapamycin derivative, preparation method, pharmaceutical composition and uses thereof | INST PHARMACOLOGY & TOXICOLOGY ACAD MILITARY MEDICAL SCIENCES PLA CHINA | 2016-04-06 | — | — | CN | claimed |
| EP-4695242-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| US-20250333405-A1 | ANTAGONISTS OF GPR39 PROTEIN | VASOCARDEA INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250158123-A1 | NONAQUEOUS ELECTROLYTE FOR NONAQUEOUS-ELECTROLYTE CELL, AND NONAQUEOUS-ELECTROLYTE CELL | PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) | 2025-05-15 | — | — | US | disclosed |
| CN-119874654-A | Pyran compound as plant immune activator and application thereof | 华东理工大学 | 2025-04-25 | — | — | CN | disclosed |
| EP-4475256-A1 | NONAQUEOUS ELECTROLYTE FOR NONAQUEOUS-ELECTROLYTE CELL, AND NONAQUEOUS-ELECTROLYTE CELL | Panasonic Intellectual Property Management Co., Ltd. (JP) | 2024-12-11 | — | — | EP | disclosed |
| US-12162961-B2 | Specific materials that can be used for the detection of at least one alkaline element | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2024-12-10 | — | — | US | disclosed |
| EP-4452263-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A P2X3 RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2024-10-30 | — | — | EP | disclosed |
| EP-2080761-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-07-22 | — | — | EP | disclosed |
| EP-2080761-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-07-22 | — | — | EP | disclosed |
| WO-2009042694-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009015369-A2 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| EP-1149094-B1 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2004-04-21 | — | — | EP | disclosed |
| US-6376491-B1 | BENZOFURAN DERIVATIVES FOR TREATMENT OR PREVENTION OF MYCOSIS IN MAMMALS | BASILEA PHARMACEUTICA AG (CH) | 2002-04-23 | — | — | US | disclosed |
| EP-1149094-A2 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | Basilea Pharmaceutica AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000037464-A2 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2000-06-29 | — | — | WO | disclosed |